Feature

Research Reports

Health Care Use and Costs Among Medicare Patients With Chronic Obstructive Pulmonary Disease Treated With Short-Acting Beta Agonists or Long-Acting Beta Agonists

04/11/2016

Vamsi K. Bollu , PhD, MBA;

Flavia Ejzykowicz , PhD;

Joel W. Hay , PhD;

Krithika Rajagopalan , PhD;

Abstract: Chronic obstructive pulmonary disease (COPD) has a high prevalence among older adults and is the third leading cause of mortality in the United States. COPD exacerbations can require hospitalizations,...

...

04/11/2016

Journal of Clinical Pathways

Perspectives

Impact of Government Cost Controls on Treatment Selection for Clinical Pathways

03/08/2016

Scott Guerin , PhD;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Abstract: The increasing emphasis on value-based care has led to the rise of clinical pathways and their use in various health care settings for a number of different disease states. To improve these pathways and...

...

03/08/2016

Journal of Clinical Pathways

Research Reports

Effect of Route of Bortezomib Administration on Treatment Outcomes in Previously Untreated Patients with Multiple Myeloma: A Retrospective Analysis from US Community Oncology Practices

03/08/2016

Liviu Niculescu , MD;

Robyn Harrell , MS;

Lina Asmar , PhD;

Yanyan Zhu , PhD, MPH;

Esprit Ma , MPH;

Vijayveer Bonthapally , PhD;

Robert M. Rifkin , MD, FACP;

Abstract: A phase 3 study (MMY-3021) in relapsed/refractory multiple myeloma (MM) demonstrated non-inferior efficacy and an improved systemic safety profile with subcutaneous (SC) versus intravenous (IV) bortezomib....

...

03/08/2016

Journal of Clinical Pathways

Perspectives

The Role of Patient Navigation in Improving the Value of Oncology Care

02/16/2016

Cortney Riley , BS, DPT;

Sheryl Riley , RN, OCN, CMCN;

Abstract: Today, cancer patients face many challenges when trying to understand and navigate the health care system. These challenges begin at the time of diagnosis and continue throughout treatment, follow-up care,...

...

02/16/2016

Journal of Clinical Pathways

From the Field

Facilitating Physician Adherence to Clinical Pathways Across a Multi-Site Oncology Practice Network

02/16/2016

Brian J. Gebhardt , MD;

Sushil Beriwal , MD;

Dwight E. Heron , MD, MBA, FACRO, FACR;

Abstract: With so many new developments in the field on oncology, physicians have a difficult time staying abreast of new guidelines and recommendations for different disease states. Clinical pathways are an...

...

02/16/2016

Journal of Clinical Pathways

Perspectives

Formulary Decisions and the Evolution of Psoriasis Treatment

12/14/2015

Steven R. Feldman , MD, PhD;

William Malatestinic , PharmD, MBA;

David Amato , MD;

Abstract: Psoriasis is a common and significant illness characterized by systemic inflammation. In its mildest form, psoriasis can often be managed with relatively low-cost topical therapies; but for...

...

12/14/2015

Journal of Clinical Pathways

Research Reports

A Clinical Pathway to Reduce Time to Antibiotic Administration in Pediatric Cancer Patients With Fever and Potential Neutropenia

12/14/2015

Susan Lindemulder , MD, MCR;

Thuan Nguyen , MD, PhD;

Adam Lamble , MD;

David M. Spiro , MD, MPH;

Dawn Nolt , MD, MPH;

Linda C. Stork , MD;

Suman Malempati , MD;

Abstract: The authors developed a novel clinical pathway in the pediatric emergency department (PED) of Doernbecher Children’s Hospital, Oregon Health & Science University, that endorses administering...

...

12/14/2015

Journal of Clinical Pathways

Perspectives

The Use of Risk-Sharing Agreements to Manage Costs, Mitigate Risk, and Improve Value for Pharmaceutical Products

10/28/2015

Alex Bastian , MBA;

Sahand Mirzahossein , MBA;

Deeksha Dua , MBBS, MPH;

In this article, the authors review the types of RSAs that have been implemented to date, with a specific focus on two European countries (the United Kingdom and Italy) and on the United States.

In this article, the authors...

10/28/2015

Journal of Clinical Pathways

Research Reports

The Use of Incremental Cost-Effectiveness Ratio Thresholds in Health Technology Assessment Decisions

10/27/2015

Abner Nyandege , PhD;

Mkaya Mwamburi , MD, PhD, MA;

Anagha Gogate , BA;

Merena Nanavaty , MS, BPharm;

Zeba M. Khan , RPh, PhD;

Satyin Kaura , MSc, MBA;

John Proach , MBA;

Abstract: The incremental cost-effectiveness ratio (ICER) is used to determine the cost-effectiveness of new health care interventions. A literature review was conducted to determine the ICER thresholds used by...

...

10/27/2015

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Feature

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products